Virax Biolabs Group Limited VRAX
1.20 USD +0.14 (+12.74%)
Nov 4, 2026, 1:16 PM EST
1.11 Day range 1.57
1.04 52-week range 21.75
- YTD
- -86.18%
- 1 year
- -90.63%
Financial health
Altman Z-Score
-6.55 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B3 / 5 overall
- DCF 5
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 5
Valuation
P/E -0.4×
FY 2020 5y median -0.6× FY 2026
P/S 176×
FY 2020 5y median 176× FY 2026
P/B 0.3×
FY 2020 5y median 0.3× FY 2026
P/FCF -0.4×
FY 2020 5y median -0.7× FY 2026
EV/EBITDA 0.7×
FY 2020 5y median 0.3× FY 2026
EV/Sales -309×
FY 2020 5y median -50.7× FY 2026
FCF Yield -223.1%
FY 2020 5y median -146.4% FY 2026
Profitability
Gross Margin 61.9%
FY 2020 5y median 0.0% FY 2026
Operating Margin -51515.2%
FY 2020 5y median -51515.2% FY 2026
Net Margin -40439.1%
FY 2020 5y median -40439.1% FY 2026
ROE -66.3%
FY 2020 5y median -66.3% FY 2026
ROIC -70.1%
FY 2020 5y median -70.1% FY 2026
ROA -60.3%
FY 2020 5y median -94.3% FY 2026
Growth (YoY)
Revenue 96.2%
FY 2020 FY 2026
Operating Income -3.8%
FY 2020 FY 2026
EPS (diluted) 74.1%
FY 2020 FY 2026
Free Cash Flow 5.6%
FY 2020 FY 2026
Financial Health
Current Ratio 10.0×
FY 2020 5y median 10.0× FY 2026
Quick Ratio 9.9×
FY 2020 5y median 9.9× FY 2026
Debt / Equity 0.1×
FY 2020 5y median 0.0× FY 2026
Net Debt / EBITDA 1.1×
FY 2020 5y median 1.1× FY 2026
Interest Coverage -104×
FY 2020 5y median -112× FY 2026
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2026
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2026
Annual · latest fiscal year ends 2026-03-31